Sight Sciences Announces Publication of Historical Review of Canal Surgery in the Glaucoma Issue of Current Opinion in Ophthalmology

MARCH 31, 2020

Sight Sciences, Inc., a growth-stage medical device company focused on transforming the treatment of glaucoma and dry eye disease, today announced that a review of the history of canal surgery in glaucoma, by Jaime Dickerson, Ph.D., and Reay Brown, M.D., has been published in Current Opinion in Ophthalmology. The review, titled “Circumferential canal surgery: a 
+ Read More


Sight Sciences Announces $30 Million Financing Led by D1 Capital Partners

MARCH 18, 2020

Sight Sciences, Inc., a growth-stage medical device company transforming the two fastest growing segments in ophthalmology and optometry, glaucoma and dry eye disease, today announced the closing of an over $30 million Series E Preferred Stock financing round led by D1 Capital Partners. Proceeds will be used for continued clinical and operational development and to 
+ Read More


Sight Sciences Announces Publication of First-Ever Multicenter MIGS study in Childhood Glaucoma

MARCH 10, 2020

Sight Sciences, Inc., a growth-stage medical device company transforming the two fastest-growing segments in ophthalmology and optometry, glaucoma and dry eye disease, today announced that positive outcomes from a new multicenter study of one of the OMNI® Surgical System’s predecessor devices, TRAB®360, were published in the American Journal of Ophthalmology. Following a 2019 publication1 of 
+ Read More


Sight Sciences Appoints Erica Rogers to its Board of Directors

DECEMBER 09, 2019

Sight Sciences, Inc., a growth-stage medical device company transforming the two fastest growing segments in ophthalmology and optometry, glaucoma and dry eye disease, today announced the appointment of Erica Rogers to the company’s board of directors. Ms. Rogers, President and CEO of Silk Road Medical (NASDAQ: SILK), is an experienced leader and entrepreneur in the 
+ Read More


International MIGS Study Confirms Long-Term Safety and Efficacy of the OMNI® Surgical System Predicate Device (VISCO360®)

OCTOBER 22, 2019

Sight Sciences, Inc., today announced a new, single center study of glaucoma surgery patients published in the July 2019 issue of Clinical Ophthalmology, which shows that ab-interno microcatheterization and 360˚ viscodilation of Schlemm’s Canal using one of the OMNI® Surgical System’s predicate devices (VISCO360®) provides a favorable safety profile and substantial long-term reductions in both 
+ Read More


First International MIGS Data for the OMNI® Surgical System Presented at ESCRS

SEPTEMBER 21, 2019

Sight Sciences announced clinical results from the first study of the OMNI® Surgical System in glaucoma patients were presented at the European Society of Cataract and Refractive Surgery (ESCRS). Findings from the pilot study suggest the OMNI® Surgical System, which is dually indicated in Europe for the sequential ab interno procedures of microcatheterization and transluminal 
+ Read More


Sight Sciences Raises $56M of Growth Capital to Lead the Development of the Standalone MIGS Market and Procedure-Based Dry Eye Market

SEPTEMBER 04, 2019

Sight Sciences, Inc., a growth-stage medical device company transforming the two fastest growing segments in ophthalmology and optometry, glaucoma and dry eye disease, today announced the closing of $31 million in Series D Preferred Stock financing led by KCK Group, a leading investor in high growth medical technology companies. MidCap Financial, a prominent middle-market lender 
+ Read More


Sight Sciences Hires Leading Industry Executives to Drive Continued Growth

AUGUST 07, 2019

Sight Sciences, Inc., a growth-stage medical device company transforming the two fastest growing segments in ophthalmology and optometry, glaucoma and dry eye disease, today announced that Jessica Holmes, Brian Regan and Jim Sluck have joined the company as Vice President of Health Policy & Reimbursement, Vice President of Strategy & Professional Relations and Vice President 
+ Read More


First Subject Enrolled in large, multi-center pivotal trial to confirm safety and efficacy of TearCare® in the treatment of signs and symptoms of Dry Eye disease

JUNE 13, 2019

Sight Sciences, Inc., a growth-stage medical device company transforming the two fastest growing segments in ophthalmology and optometry, glaucoma and dry eye, today announced the first subject has been enrolled in OLYMPIA, the U.S. pivotal trial to further assess the safety and efficacy of TearCare® for patients with dry eye disease. TearCare® is the only 
+ Read More


Sight Sciences Announces Official Launches of TearCare® and the Enhanced, Next Generation OMNI® System

APRIL 30, 2019

New Dry Eye and MIGS Entrants will be Prominently Featured in Product Demonstrations and Events at Upcoming Industry Shows MENLO PARK, Calif. – Sight Sciences, Inc., a growth-stage medical device company transforming the two fastest growing segments in ophthalmology and optometry – dry eye and glaucoma – today announced the official commercial launch of TearCare® 
+ Read More